March 5, 2021 — Applying algorithms to interconnected biomarker and clinical data can yield scientific insights, not only into therapeutic mechanisms, but also into predicting long-term response to treatment.
In a collaboration with investigators at Janssen, the QuartzBio team sought to identify genetic markers correlated with protection against chronic hepatitis B early relapse in patients after withdrawal from treatment. The team identified several genes that were, for the first time, associated with protection against early onset of relapse.
